Sangeet Ghai, MD, FRCR
Dr. Sangeet Ghai is the Director of Research (JDMI) and Associate Professor in the Joint Department of Medical Imaging (JDMI) University of Toronto, Canada. He is a Clinician Scientist at Princess Margaret Cancer Centre and also the Director of Prostate Center (Princess Margaret Cancer Centre) and Biopsy Center (TGH). He completed his postgraduate training in India, with a dual fellowship in abdominal imaging and interventional radiology at UofT.
Dr. Ghai works with MRI for diagnostic and intervention purposes, with an active involvement in clinical trials testing new devices and treatments for cancer, with a focus on genito-urinary and prostate disease sites. He is working on MR guided high-intensity focused ultrasound (HIFU), MR guided focal laser ablation and photo-dynamic therapy (PDT) for prostate cancer treatment. As the lead in the development of procedural elements of both MR guided interstitial laser thermal therapy (MRgFLA) and MR guided focused ultrasound ablation (MRgFUS) studies of localized prostate cancer, he has been instrumental in optimizing protocols and treatment delivery techniques for focal therapy under MRI guidance. In addition, he is working to use novel methods to track temperature changes in ablation therapies, including novel MR sequences and diffuse optical thermal mapping, which will help with the accurate and guided delivery of therapy to tumours.
The use of ultrasound for guided interventions and screening is also an interest of Dr. Ghai’s, including performance of high-resolution ultrasound for prostate cancer screening and detection. He is also the imaging lead for a prospective observational study on active surveillance for papillary thyroid cancers.
- Micro-Ultrasound: Current Role in Prostate Cancer Diagnosis and Future Possibilities
Prostate Cancer (PCa) is the second most common cancer in men. Population screening using prostate specific antigen (PSA) blood test and digital […]
- The role of [18F]-DCFPyL PET/MRI radiomics for pathological grade group prediction in prostate cancer
CONCLUSION: The combined [^(18)F]-DCFPyL PET/MRI radiomic model was the best-performing model and outperformed the clinical model for pathological […]
- PI-RR: The Prostate Imaging for Recurrence Reporting System for MRI Assessment of Local Prostate Cancer Recurrence After Radiation Therapy or Radical Prostatectomy-A Review
This article reviews the clinical application of the Prostate Imaging for Recurrence Reporting (PI-RR) system. This system, released in 2021, […]
- Magnetic resonance imaging-guided ultrasound ablation for prostate cancer - A contemporary review of performance
Prostate cancer (PCa) is one of the most common malignancies in men, but patient outcomes are varied depending on extent of disease. Radical, […]
- Therapeutic US Applications for the Abdomen and Pelvis
US and MRI-guided therapeutic US (TUS) can aid in the treatment of prostate, liver, and pancreatic cancer, as well as uterine fibroids and osseous […]
- Beyond the AJR: MRI-Guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer
No abstract
- Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men
Background Multiparametric MRI has led to increased detection of clinically significant prostate cancer (csPCa). Micro-US is being investigated for […]
- Detection of Clinically Significant Index Prostate Cancer Using Micro-ultrasound: Correlation With Radical Prostatectomy
CONCLUSION: MicroUS showed the high sensitivity (87%) in detecting index lesions in the prostate gland and identified 100% of index lesions in the […]
- Correction to: Exploring the value of using patient‑oriented MRI reports in clinical practice - a pilot study
No abstract
- Prostate Cancer Imaging: What We Already Know and What Is on the Horizon
No abstract
- Exploring the value of using patient-oriented MRI reports in clinical practice - a pilot study
CONCLUSION: With the addition of prostate MRI PACERR, participants had better understanding of their results and felt more prepared to involve […]
- Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy
CONCLUSION: Not all men benefit equally from the combination of SBx and MRI-TBx. SBx avoidance in men with PI-RADS 5 and/or previous negative biopsy […]
- Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies
CONCLUSION: Optimally processed FNB and liquid biopsy can be used routinely for tumor mutation profiling to identify actionable mutations.
- A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer
BACKGROUND: Transrectal ultrasound (TRUS) guided biopsy for prostate cancer is prone to random and systemic error and has been shown to have a […]
- A Quantitative Analysis Examining Patients' Choice of Active Surveillance or Surgery for Managing Low-Risk Papillary Thyroid Cancer
Background: It is important to understand patient preferences on managing low-risk papillary thyroid cancer (PTC). Methods: We prospectively followed […]
- Target prostate biopsies: How best to report in synoptic format?
No abstract
- Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review
Prostate cancer (PCa) is the most common non-cutaneous cancer diagnosed in males. Traditional tools for screening and diagnosis, such as […]
- Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance
Active surveillance (AS) of small, low-risk papillary thyroid cancers (PTCs) is increasingly studied in prospective observational studies. Ultrasound […]
- Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes
No abstract
- Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer
CONCLUSION: mpMRI is able to document the morphological and temporal changes following focal therapy. It has limited ability to detect recurrent […]
- MRI Targeted Prostate Biopsy Techniques: AJR Expert Panel Narrative Review
Prostate cancer is the second most common malignancy in men worldwide. Systematic transrectal prostate biopsy is commonly used to obtain tissue to […]
- A Protocol for a Pan-Canadian Prospective Observational Study on Active Surveillance or Surgery for Very Low Risk Papillary Thyroid Cancer
BACKGROUND: The traditional management of papillary thyroid cancer (PTC) is thyroidectomy (total or partial removal of the thyroid). Active […]
- Proceedings of the Canadian Thyroid Cancer Active Surveillance Study Group 2019 national investigator meeting
Active surveillance (AS) in the management of small, low risk papillary thyroid cancer (PTC) as an alternative option to thyroidectomy, is an area of […]
- Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences
CONCLUSION: Research biopsies were generally well accepted. Most patients (83%) were willing to undergo serial biopsies if necessary. Addressing the […]
- Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer
Background In validation studies, risk models for clinically significant prostate cancer (csPCa; Gleason score ≥3+4) combining multiparametric MRI […]
- Salvage interstitial laser thermal therapy under MRI guidance (MRgFLA) for high-intensity focal ultrasound (HIFU) recurrences: feasibility study
While focal therapy (FT) is increasingly endorsed for treating localized prostate cancer in the appropriately selected patient, management of […]
- MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial
No abstract
- Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR
CONCLUSION: PSMA PET detects more csPCa than mpMR, but at low specificity. The performance PET/MR is better than mpMR for detection of csPCa in […]
- Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus
CONCLUSIONS: FT can be offered to men coming off AS between the age of 60 to 80 with grade group 2 localized cancer. This consensus from a […]
- Quantitative Prostate MRI Analysis Following Fluvastatin Therapy for Localized Prostate Cancer - A Pilot Study
CONCLUSION: mpMRI techniques may not be sufficiently sensitive to detect the types (or magnitude) of tumor cell changes observed following 6-7 weeks […]